Zobrazeno 1 - 10
of 139
pro vyhledávání: '"Andreas L. Petzer"'
Autor:
Hans Geinitz, Carsten Nieder, Lukas Kocik, Christine Track, Johann Feichtinger, Theresa Weingartner, Kurt Spiegl, Barbara Füreder-Kitzmüller, Johanna Kaufmann, Dietmar H. Seewald, Reinhold Függer, Andreas Shamiyeh, Andreas L. Petzer, David Kiesl, Josef Hammer
Publikováno v:
Radiation Oncology, Vol 15, Iss 1, Pp 1-9 (2020)
Abstract Purpose To report the long-term outcomes of neoadjuvant altered fractionation short-course radiotherapy in 271 consecutive patients with stage II-III rectal cancer. Patients and Methods: This was a retrospective single institution study with
Externí odkaz:
https://doaj.org/article/82faf28c0ab24d36943d95310f80ca2f
Autor:
Marie-Luise Hütter-Krönke, Axel Benner, Konstanze Döhner, Jürgen Krauter, Daniela Weber, Margit Moessner, Claus-Henning Köhne, Heinz A. Horst, Ingo G.H. Schmidt-Wolf, Mathias Rummel, Katharina Götze, Elisabeth Koller, Andreas L. Petzer, Hans Salwender, Walter Fiedler, Heinz Kirchen, Detlef Haase, Stephan Kremers, Matthias Theobald, Axel C. Matzdorff, Arnold Ganser, Hartmut Döhner, Richard F. Schlenk
Publikováno v:
Haematologica, Vol 101, Iss 7 (2016)
Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m2 intravenously on day 1), all-trans retinoic acid (45 mg/m2 orally on day
Externí odkaz:
https://doaj.org/article/e94817aacaec41859b402566beb720a7
Autor:
Andreas L. Petzer, Dominic Fong, Thomas Lion, Irina Dyagil, Zvenyslava Masliak, Andrija Bogdanovic, Laimonas Griskevicius, Sandra Lejniece, Stefan Goranov, Liana Gercheva, Aleksandar Stojanovic, Dontcho Peytchev, Nikolay Tzvetkov, Rasa Griniute, Atanas Stanchev, Thomas Grubinger, Marthin Kwakkelstein, Peter Schuld, Guenther Gastl, Dominik Wolf
Publikováno v:
Haematologica, Vol 97, Iss 10 (2012)
Background Previous data suggest that the response of chronic myeloid leukemia cells to imatinib is dose-dependent. The potential benefit of initial dose intensification of imatinib in pre-treated patients with chronic phase chronic myeloid leukemia
Externí odkaz:
https://doaj.org/article/93d4b1dda47c41d5987fc24d77406468
Autor:
Andreas L. Petzer, Dominik Wolf, Dominic Fong, Thomas Lion, Irina Dyagil, Zvenyslava Masliak, Andrija Bogdanovic, Laimonas Griskevicius, Sandra Lejniece, Stefan Goranov, Liana Gercheva, Aleksandar Stojanovic, Dontcho Peytchev, Nikolay Tzvetkov, Rasa Griniute, Radka Oucheva, Hanno Ulmer, Marthin Kwakkelstein, Francesca Rancati, Guenther Gastl
Publikováno v:
Haematologica, Vol 95, Iss 6 (2010)
Background Imatinib 400 mg/day is the standard treatment for patients with chronic phase chronic myeloid leukemia. Recent reports suggested higher and more rapid cytogenetic and molecular responses with higher doses of imatinib.Design and Methods In
Externí odkaz:
https://doaj.org/article/c3d88bac7c40484682c8c9be4fe83659
Autor:
Paul Sevelda, Marija Balic, Raimund Jakesz, Rupert Bartsch, Margaretha Rudas, Zsuzsanna Bago-Horvath, Martin Filipits, Georg Pfeiler, Angelika Pichler, Sophie Frantal, Austrian Breast, Christoph Tinchon, Florian Fitzal, Tea Maria Muy-Kheng, Vesna Bjelic-Radisic, Herbert Stoeger, Andreas L. Petzer, Peter Dubsky, Christian F. Singer, Edgar Petru, Ruth Exner, Richard Greil, Viktor Wette, Daniel Egle, Michael Hubalek, Michael Gnant
Publikováno v:
British Journal of Cancer. 124:1795-1802
Background Preoperative chemotherapy containing anthracyclines and taxanes is well established in early-stage breast cancer. Previous studies have suggested that the chemotherapy sequence may matter but definitive evidence is missing. ABCSG trial 34
Autor:
Margit Sandholzer, August Zabernigg, Florian Roitner, Daniel Egle, Michael Knauer, Richard Greil, Sonja Heibl, Christoph Tinchon, Daniela Voskova, Michael Hubalek, Gabriel Rinnerthaler, Andreas L. Petzer, Christoph Suppan, Johannes Andel, Simon Peter Gampenrieder, Christian F. Singer
Publikováno v:
Cancer Research. 81:PS12-21
Background: International guidelines recommend endocrine-based first-line therapy [ET] in hormone receptor-positive, HER2-negative (HR+/HER2- or luminal) metastatic breast cancer (MBC), nowadays in combination with a CDK4/6 inhibitor. Several real-wo
Autor:
Michael Knauer, Gabriel Rinnerthaler, Sonja Heibl, Simon P. Gampenrieder, Richard Greil, Johannes Andel, August Zabernigg, Andreas L. Petzer, Christoph Suppan, Margit Sandholzer, Christian F. Singer, Daniel Egle, Daniela Voskova, Christoph Tinchon, Florian Roitner, Michael Hubalek
Publikováno v:
Cancer Research. 81:PS1-41
Background: Metastatic breast cancer (MBC) is generally thought to be a systemic and incurable disease requiring systemic therapy. However, surgical resection of oligometastatic disease might be of benefit similar to other malignant diseases. Here, w
Autor:
Thomas Melchardt, Thamer Sliwa, Veronika Buxhofer-Ausch, Heinz Gisslinger, Sonja Heibl, Andreas L. Petzer, Klaus Geissler, Peter Krippl, Christine Beham-Schmid, Dominik Wolf, Albert Wölfler, Maria Theresa Krauth
Publikováno v:
Wiener klinische Wochenschrift. 133:52-61
According to the World Health Organization (WHO) classification, essential (primary) thrombocythemia (ET) is one of several Bcr-Abl negative chronic myeloproliferative neoplasms (MPN). The classical term MPN covers the subcategories of MPN: ET, polyc
Autor:
Katja Weisel, David Berry, Eberhard Gunsilius, Bela Hausmann, Niklas Zojer, Andreas L. Petzer, Martin Schreder, Daniel Lechner, Richard Greil, Stefan Knop, Karl Jochen Krenosz, Hermann Einsele, Heinz Ludwig, Alois Lang, Roman Hájek, Wolfram Pönisch, Alexander Egle
Publikováno v:
eJHaem. 2:99-103
Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib-thalidomide-dexamethasone. Increased alp
Autor:
Andreas L. Petzer
Publikováno v:
memo - Magazine of European Medical Oncology. 14:257-259
SummaryChronic myeloid leukemia is nowadays associated with a good prognosis and an excellent life expectancy. However, certain levels of responses have to be achieved with the various available tyrosine kinase inhibitors at certain time points durin